Recursion Pharmaceuticals, Inc. (RXRX) Stock: Price, Forecast & Analyst Target
Recursion Pharmaceuticals, Inc. (RXRX) — MoonshotScore 17/100 (Weak band), calculated Oct 4, 2026. Price $4.12 (+1.23%), as of the Oct 2, 2026 trading session; market cap $2.16B.
Educational signal · not a buy or sell recommendation · How to read this
Recursion Pharmaceuticals, Inc. · RXRX · NASDAQ
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging technology to industrialize drug discovery. The company is focused on decoding biology through integrating technological innovations across various scientific domains.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Recursion Pharmaceuticals (RXRX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality and stalling growth, though the balance sheet is only middling. Business Quality: Poor; Financial Safety: Okay; Valuation: Rich; Growth Durability: Fading; Momentum: Rising.
- quarterly revenue $8M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 3 of 8
- Altman Z 0.77 · Piotroski F 3
Holding back: weak fundamentals, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 16 | Weak | |
| 15 | Weak | |
| 14 | Weak | |
| 14 | Weak | |
| 18 | Weak | |
| 18 | Weak |
The score was 17 in the stored Oct 3, 2026 snapshot and remains 17 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Business Quality -1 and Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $4.12 |
| Change on the day | +1.23% |
| 52-week range | $2.77 – $7.18 |
| Market capitalisation | $2.16B |
| Price / earnings (trailing) | -3.56 |
| Shares traded on the day | 18.84M |
Price & events
Other perspectives
Council score for Recursion Pharmaceuticals (RXRX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 3, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the RXRX film — every key number, told as a short cinematic story
~2 min · open the film
What is Recursion Pharmaceuticals (RXRX), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Recursion Pharmaceuticals, Inc. (RXRX) is listed on NASDAQ. It employs 600 people and is led by Najat Khan. In Q2 FY2026 it reported revenue of $8M and net income of -$131M. The market values it at $2.16B.
What do the latest results show for Recursion Pharmaceuticals (RXRX)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $8M. Against analyst estimates the company has EPS beat 3 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $8M | -$131M | -$0.25 (diluted) |
| Q1 FY2026 | $6M | -$118M | -$0.22 (diluted) |
| Q4 FY2025 | $36M | -$108M | -$0.21 (diluted) |
| Q3 FY2025 | $5M | -$162M | -$0.36 (diluted) |
What are the financial strengths and risks for Recursion Pharmaceuticals (RXRX)?
Short answer
What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z 0.77 · Piotroski F 3. Trailing ratios: ROE -50.4% · ROA -42.8% · current ratio 5.03 · earnings yield -23.9% · free-cash-flow yield -16.6%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.77 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-50.4%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
What should you watch next at Recursion Pharmaceuticals (RXRX)?
Short answer · as of
Current published price targets run low $5.30 · high $5.30 · consensus $5.30 · median $5.30 against a quoted price of $4.12 (as of Oct 2, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Recursion Pharmaceuticals compare with its peers?
Short answer
Recursion Pharmaceuticals's score ranks 3rd of 4 in the bounded comparison shown, against 3 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $31.02 Oct 2, 2026 | $5.30B | 53 5-pillar Oct 4, 2026 | |
| $24.50 Oct 2, 2026 | $2.52B | 28 5-pillar Oct 4, 2026 | |
| Recursion Pharmaceuticals (RXRX) — this page | $4.12 | $2.16B | 17 |
| $10.29 Oct 2, 2026 | $10.8B | 13 5-pillar Oct 4, 2026 | |
| $11.74 Date unavailable | $2.18B | — Model unavailable | |
| $9.72 Date unavailable | $2.25B | — Model unavailable | |
| $40.15 Date unavailable | $2.06B | — Model unavailable | |
| $15.83 Date unavailable | $2.04B | — Model unavailable | |
| $39.64 Date unavailable | $2.29B | — Model unavailable | |
| $13.91 Date unavailable | $1.97B | — Model unavailable | |
| $28.64 Date unavailable | $2.55B | — Model unavailable | |
| $58.51 Date unavailable | $2.78B | — Model unavailable | |
| $55.36 Date unavailable | $1.52B | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $5.30 – $5.30
- Consensus target
- $5.30
- Median target
- $5.30
Consensus record · Captured .
Measured against a quoted price of $4.12 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 42
- Identified insiders
- 11
- Purchases
- 0
- Sales
- 13
- Other transactions
- 29
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Recursion Pharmaceuticals (RXRX)?
Common Questions About RXRX
These answers are editorial: 1 of these 9 answers is drawn from the RXRX research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for RXRX?
RXRX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging technology to industrialize drug discovery.
Is RXRX a good stock to buy?
Stock Expert AI does not rate RXRX buy, sell or hold. Recursion Pharmaceuticals, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RXRX stock price today?
The last price recorded on this page for Recursion Pharmaceuticals, Inc. (RXRX) is $4.12, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RXRX price target?
The analyst consensus price target for Recursion Pharmaceuticals, Inc. (RXRX) is $5.30 (range $5.30 to $5.30, median $5.30), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for RXRX?
The main risks for Recursion Pharmaceuticals, Inc. include the potential failure of clinical trials for its key drug candidates, regulatory delays in obtaining drug approvals, and competition from other biotechnology companies.
What are the key factors to evaluate for RXRX?
Recursion Pharmaceuticals, Inc. (RXRX) holds a MoonshotScore in the low range. Analysts target $5.30 (+29%). This is an ongoing process with continuous improvements. Not financial advice.
How frequently does RXRX data refresh on this page?
RXRX's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RXRX's recent stock price performance?
Recursion Pharmaceuticals, Inc. (RXRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology platform for drug discovery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RXRX overvalued or undervalued right now?
Recursion Pharmaceuticals, Inc. (RXRX) is loss-making, so its trailing P/E is negative (-3.56x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Analysts target $5.30 (+29%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (22 figures)
The 22 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 14 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $4.12 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T20:54:40.633Z. | |
px.change | Change on the day | +1.23% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $2.16B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T20:54:39.019Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.05 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $8M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | -3.56 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 18.84M | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q2 FY2026 | -$131M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $5.30 · high $5.30 · consensus $5.30 · median $5.30 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $5.30 – $5.30 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $5.30 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $5.30 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 42 transactions · 0 purchases, 13 sales, 29 other transactions · 11 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Oct 1, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 0.77 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
px.range52 | 52-week range | $2.77 – $7.18 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.employees | Employees | 600 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.ceo | Chief executive | Najat Khan | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -50.4% · ROA -42.8% · current ratio 5.03 · earnings yield -23.9% · free-cash-flow yield -16.6% | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 17 of 100 · Weak · pillars 15 / 43 / 36 / 21 / 66 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 17 (stored snapshot Oct 3, 2026) → 17 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.